Which item is NOT commonly considered by the FDA when deciding on REMS?

Which item is NOT commonly considered by the FDA when deciding on REMS?

• A. Seriousness of the disease
• B. Seriousness of side effects
• C. Benefit of the drug
• D. Cost of drug development

Answer: (C)

The main idea here is how FDA decides on REMS by weighing risk management needs against the drug’s context. When determining a REMS, FDA looks at how serious the disease being treated is and how severe or potentially irreversible the drug’s adverse effects could be, because more serious conditions or harms often justify stricter risk-mitigation measures and required monitoring or education to ensure safe use. The drug’s benefit is also part of the decision in the sense that REMS are meant to balance risks with meaningful therapeutic benefit, ensuring that any restrictions still allow patients to access a beneficial therapy. What isn’t a driver of REMS decisions is how much it cost to develop the drug; development costs don’t influence the safety-related controls or distribution restrictions that REMS impose.

The main idea here is how FDA decides on REMS by weighing risk management needs against the drug’s context. When determining a REMS, FDA looks at how serious the disease being treated is and how severe or potentially irreversible the drug’s adverse effects could be, because more serious conditions or harms often justify stricter risk-mitigation measures and required monitoring or education to ensure safe use. The drug’s benefit is also part of the decision in the sense that REMS are meant to balance risks with meaningful therapeutic benefit, ensuring that any restrictions still allow patients to access a beneficial therapy. What isn’t a driver of REMS decisions is how much it cost to develop the drug; development costs don’t influence the safety-related controls or distribution restrictions that REMS impose.